{"success":true,"data":{"pressRelease":{"id":"67572","rtpr_id":"nPn9JcS9wa","ticker":"CPIX","exchange":"NASDAQ","all_tickers":["CPIX","RDHL","2RHY"],"title":"RedHill Biopharma Announces Up To $19.4 Million Private Placement","author":"PR Newswire","published_at":"2026-06-18T12:00:06.646Z","article_body":"RedHill Biopharma Announces Up To $19.4 Million Private Placement\n\nPR Newswire\n\nTEL AVIV, Israel & RALEIGH, N.C., June 18, 2026\n\n$6 million upfront with up to approximately $13.4 million of potential\naggregate gross proceeds upon the exercise in full of warrants\n\nTEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill\nBiopharma Ltd. (https://www.redhillbio.com/home/default.aspx) (Nasdaq: RDHL)\n(\"RedHill\" or the \"Company\"), a specialty biopharmaceutical company, today\nannounced that it has entered into a definitive agreement for the purchase and\nsale of an aggregate of 8,571,429 American Depositary Shares (\"ADSs\") (or ADS\nequivalents in lieu thereof), each ADS representing ten thousand (10,000)\nordinary shares of the Company, series A-1 warrants to purchase up to an\naggregate of 8,571,429 ADSs and series A-2 warrants to purchase up to an\naggregate of 8,571,429 ADSs, at a combined purchase price of $0.70 per ADS (or\nADS equivalent in lieu thereof) and accompanying warrants in a private\nplacement. The Series A-1 warrants have an exercise price of $0.86 per ADS,\nare exercisable immediately and have a term of five years following the\nEffectiveness Date (as defined below), and the Series A-2 warrants have an\nexercise price of $0.70 per ADS, are exercisable immediately and have a term\nof 18 months following the Effectiveness Date. The private placement is\nexpected to close on June 22, 2026, subject to the satisfaction of customary\nclosing conditions.\n\nH.C. Wainwright & Co. is acting as the exclusive placement agent for the\noffering.\n\nThe gross proceeds to the Company from this offering are expected to be\napproximately $6 million, before deducting the placement agent's fees and\nother offering expenses payable by the Company. The potential additional gross\nproceeds to the Company from the series A-1 warrants and the series A-2\nwarrants, if fully exercised on a cash basis, will be approximately $13.4\nmillion. No assurance can be given that any of the series warrants will be\nexercised, or that the Company will receive cash proceeds from the exercise of\nthe series warrants.\n\nThe Company intends to use a portion of the net proceeds to support a\npotential strategic product acquisition and the balance for working capital,\nresearch and development and general corporate purposes.\n\nNo definitive acquisition agreement has been executed, and any such\ntransaction would remain subject to completion of definitive documentation,\nfinancing and other customary conditions. There can be no assurance that any\nsuch transaction will be completed.\n\nThe securities described above were offered in a private placement under\nSection 4(a)(2) of the Securities Act of 1933, as amended (the \"Securities\nAct\"), and/or Regulation D promulgated thereunder and, along with the ordinary\nshares of the Company represented by ADSs underlying the warrants, have not\nbeen registered under the Securities Act or applicable state securities laws.\nAccordingly, the securities issued in the private placement and ordinary\nshares of the Company represented by ADSs underlying the warrants may not be\noffered or sold in the United States except pursuant to an effective\nregistration statement or an applicable exemption from the registration\nrequirements of the Securities Act and such applicable state securities laws.\nPursuant to a registration rights agreement with the investors, the Company\nhas agreed to file a resale registration statement covering the securities\ndescribed above (such date of effectiveness of the resale registration\nstatement, the \"Effectiveness Date\").\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or other jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout RedHill Biopharma\n\nRedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical\ncompany primarily focused on U.S. development and commercialization of drugs\nfor gastrointestinal diseases, infectious diseases and\noncology. RedHill promotes the FDA-approved gastrointestinal\ndrug Talicia(®,) for the treatment of Helicobacter pylori (H.\npylori) infection in adults(([1])), with a U.S. co-commercialization\nagreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key\nclinical late-stage development programs include: (i) opaganib (ABC294640), a\nfirst-in-class, orally administered sphingosine kinase-2 (SPHK2) selective\ninhibitor with anti-inflammatory, antiviral, metabolic and anticancer\nactivity, targeting multiple indications with U.S. government and academic\ncollaborations intended for medical countermeasure development including for\nEbola virus disease, radiation exposure indications such as GI-Acute Radiation\nSyndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an\nongoing Phase 2 study in prostate cancer in combination with Bayer's\ndarolutamide; (ii) RHB-102 (Bekinda®), with a planned Phase 2\nproof-of-concept study for GLP-1/GIP receptor agonist-associated GI\nintolerance, positive results from a U.S. Phase 3 study for acute\ngastroenteritis and gastritis, positive results from a U.S. Phase 2 study\nfor IBS-D and potential UK submission for chemotherapy and radiotherapy\ninduced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals\n(EBR: HYL) for worldwide development and commercialization outside North\nAmerica; (iii) RHB-204, a next-generation optimized formulation of RHB-104,\nwith a planned Phase 2 study for Crohn's disease (based on RHB-104's positive\nPhase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an\noral broad-acting, host-directed, serine protease inhibitor with potential\nfor pandemic preparedness, including COVID-19 and also targeting multiple\ncancer and inflammatory gastrointestinal diseases.\n\nMore information about the Company is available at www.redhillbio.com\n(https://www.redhillbio.com/home/default.aspx)  / X.com/RedHillBio\n(https://x.com/RedHillBio) .\n\nForward Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of\nthe Private Securities Litigation Reform Act of 1995 and may discuss\ninvestment opportunities, stock analysis, financial performance, investor\nrelations, and market trends. Such statements may be preceded by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords and include, among others, the consummation of the offering and the\nsatisfaction of customary closing conditions related to the offering, the use\nof proceeds therefrom, the potential exercise of the series warrants and\npotential proceeds therefrom, potential acquisition of strategic products,\nstatements regarding the potential submission of Talicia® for UK Marketing\nAuthorisation and any approval thereof and statements regarding the potential\neffects of Talicia® in the treatment of Helicobacter pylori infection.\nForward-looking statements are based on certain assumptions and are subject to\nvarious known and unknown risks and uncertainties, many of which are beyond\nthe Company's control and cannot be predicted or quantified, and consequently,\nactual results may differ materially from those expressed or implied by such\nforward-looking statements. Such risks and uncertainties include, without\nlimitation: market and other conditions, the risk that the MAA submission for\nTalicia may not be approved; the risk that the Company will not succeed in its\nenforcement action against Kukbo, and if successful may not recover all or any\nof awards granted by the New York Supreme Court; the risk that opaganib does\nnot receive a priority review voucher, marketing exclusivity or accelerated\ndevelopment and review times; the risk that opaganib is not accepted into\nEbola virus disease control programs, or if accepted, that it does not\ndemonstrate efficacy; the risk that development of RHB-204 for Crohn's disease\nmay not be completed, or if completed may not be approved or may not achieve\ncommercial success; the risk that opaganib is not effective against the\nindications for which we develop our products; the risk that RHB-102 (Bekinda)\ndoes not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea;\nthe risk regarding the Company's ability to regain and maintain compliance\nwith Nasdaq's listing requirements, including the minimum bid price\nrequirement; the risk that the addition of new revenue generating products or\nout-licensing transactions will not occur; the risk that the Company will not\nreceive future milestone payments under its existing agreements or that they\nwill be less than anticipated; the risk of current uncertainty regarding U.S.\ngovernment research and development funding and that the U.S. government is\nunder no obligation to continue to support development of our products and can\ncease such support at any time; the risk that acceptance onto the RNCP Product\nDevelopment Pipeline or other governmental and non-governmental development\nprograms will not guarantee ongoing development or that any such development\nwill not be completed or successful; the risk that the FDA does not agree with\nthe Company's proposed development plans for its programs; the risk that the\nCompany's development programs and studies may not be successful and, even if\nsuccessful, such studies and results may not be sufficient for regulatory\napplications, including emergency use or marketing applications, and that\nadditional studies may be required; the risk that the Company will not\nsuccessfully commercialize its products; as well as risks and uncertainties\nassociated with (i) the initiation, timing, progress and results of the\nCompany's research, manufacturing, pre-clinical studies, clinical trials, and\nother therapeutic candidate development efforts, and the timing of the\ncommercial launch of its commercial products and ones it may acquire or\ndevelop in the future; (ii) the Company's ability to advance its therapeutic\ncandidates into clinical trials or to successfully complete its pre-clinical\nstudies or clinical trials or the development of any necessary commercial\ncompanion diagnostics; (iii) the extent and number and type of additional\nstudies that the Company may be required to conduct and the Company's receipt\nof regulatory approvals for its therapeutic candidates, and the timing of\nother regulatory filings, approvals and feedback; (iv) the manufacturing,\nclinical development, commercialization, and market acceptance of the\nCompany's therapeutic candidates and Talicia; (v) the Company's ability to\nsuccessfully commercialize and promote Talicia; (vi) the Company's ability to\nestablish and maintain corporate collaborations; (vii) the Company's ability\nto acquire products approved for marketing in the U.S. that achieve commercial\nsuccess and build its own marketing and commercialization capabilities; (viii)\nthe interpretation of the properties and characteristics of the Company's\ntherapeutic candidates and the results obtained with its therapeutic\ncandidates in research, pre-clinical studies or clinical trials; (ix) the\nimplementation of the Company's business model, strategic plans for its\nbusiness and therapeutic candidates; (x) the scope of protection the Company\nis able to establish and maintain for intellectual property rights covering\nits therapeutic candidates and its ability to operate its business without\ninfringing the intellectual property rights of others; (xi) parties from whom\nthe Company licenses its intellectual property defaulting in their obligations\nto the Company; (xii) the Company's ability to collect on its judgment against\nKukbo; (xiii) estimates of the Company's expenses, future revenues, capital\nrequirements and needs for additional financing; (xiv) the effect of patients\nsuffering adverse experiences using investigative drugs under the Company's\nExpanded Access Program; (xv) competition from other companies and\ntechnologies within the Company's industry; and (xvi) the hiring and\nemployment commencement date of executive managers. More detailed information\nabout the Company and the risk factors that may affect the realization of\nforward-looking statements is set forth in the Company's filings with the\nSecurities and Exchange Commission (SEC), including the Company's Annual\nReport on Form 20-F filed with the SEC on April 27, 2026. All forward-looking\nstatements included in this press release are made only as of the date of this\npress release. The Company assumes no obligation to update any written or oral\nforward-looking statement, whether as a result of new information, future\nevents or otherwise unless required by law.\n\nCategory: Financials\n\n([1])Talicia(®) (omeprazole magnesium, amoxicillin and rifabutin) is\nindicated for the treatment of H. pylori infection in adults. For full\nprescribing information see: www.Talicia.com (https://www.talicia.com/) .\n\nLogo -\nhttps://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg\n(https://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg)\n\nCompany contact:\n\nAdi Frish\nChief Corporate & Business Development Officer\nRedHill Biopharma\nadi@redhillbio.com (mailto:adi@redhillbio.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html\n(https://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html)\n\nSOURCE RedHill Biopharma Ltd.\n\n\n\n+972-54-6543-112\n\nPhoto: \nhttp://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9JcS9wa","title":"RedHill Biopharma Announces Up To $19.4 Million Private Placement","author":"PR Newswire","ticker":"CPIX","created":"2026-06-18T12:00:06.646Z","tickers":["CPIX","RDHL","2RHY"],"exchange":"NASDAQ","article_body":"RedHill Biopharma Announces Up To $19.4 Million Private Placement\n\nPR Newswire\n\nTEL AVIV, Israel & RALEIGH, N.C., June 18, 2026\n\n$6 million upfront with up to approximately $13.4 million of potential\naggregate gross proceeds upon the exercise in full of warrants\n\nTEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill\nBiopharma Ltd. (https://www.redhillbio.com/home/default.aspx) (Nasdaq: RDHL)\n(\"RedHill\" or the \"Company\"), a specialty biopharmaceutical company, today\nannounced that it has entered into a definitive agreement for the purchase and\nsale of an aggregate of 8,571,429 American Depositary Shares (\"ADSs\") (or ADS\nequivalents in lieu thereof), each ADS representing ten thousand (10,000)\nordinary shares of the Company, series A-1 warrants to purchase up to an\naggregate of 8,571,429 ADSs and series A-2 warrants to purchase up to an\naggregate of 8,571,429 ADSs, at a combined purchase price of $0.70 per ADS (or\nADS equivalent in lieu thereof) and accompanying warrants in a private\nplacement. The Series A-1 warrants have an exercise price of $0.86 per ADS,\nare exercisable immediately and have a term of five years following the\nEffectiveness Date (as defined below), and the Series A-2 warrants have an\nexercise price of $0.70 per ADS, are exercisable immediately and have a term\nof 18 months following the Effectiveness Date. The private placement is\nexpected to close on June 22, 2026, subject to the satisfaction of customary\nclosing conditions.\n\nH.C. Wainwright & Co. is acting as the exclusive placement agent for the\noffering.\n\nThe gross proceeds to the Company from this offering are expected to be\napproximately $6 million, before deducting the placement agent's fees and\nother offering expenses payable by the Company. The potential additional gross\nproceeds to the Company from the series A-1 warrants and the series A-2\nwarrants, if fully exercised on a cash basis, will be approximately $13.4\nmillion. No assurance can be given that any of the series warrants will be\nexercised, or that the Company will receive cash proceeds from the exercise of\nthe series warrants.\n\nThe Company intends to use a portion of the net proceeds to support a\npotential strategic product acquisition and the balance for working capital,\nresearch and development and general corporate purposes.\n\nNo definitive acquisition agreement has been executed, and any such\ntransaction would remain subject to completion of definitive documentation,\nfinancing and other customary conditions. There can be no assurance that any\nsuch transaction will be completed.\n\nThe securities described above were offered in a private placement under\nSection 4(a)(2) of the Securities Act of 1933, as amended (the \"Securities\nAct\"), and/or Regulation D promulgated thereunder and, along with the ordinary\nshares of the Company represented by ADSs underlying the warrants, have not\nbeen registered under the Securities Act or applicable state securities laws.\nAccordingly, the securities issued in the private placement and ordinary\nshares of the Company represented by ADSs underlying the warrants may not be\noffered or sold in the United States except pursuant to an effective\nregistration statement or an applicable exemption from the registration\nrequirements of the Securities Act and such applicable state securities laws.\nPursuant to a registration rights agreement with the investors, the Company\nhas agreed to file a resale registration statement covering the securities\ndescribed above (such date of effectiveness of the resale registration\nstatement, the \"Effectiveness Date\").\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or other jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout RedHill Biopharma\n\nRedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical\ncompany primarily focused on U.S. development and commercialization of drugs\nfor gastrointestinal diseases, infectious diseases and\noncology. RedHill promotes the FDA-approved gastrointestinal\ndrug Talicia(®,) for the treatment of Helicobacter pylori (H.\npylori) infection in adults(([1])), with a U.S. co-commercialization\nagreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key\nclinical late-stage development programs include: (i) opaganib (ABC294640), a\nfirst-in-class, orally administered sphingosine kinase-2 (SPHK2) selective\ninhibitor with anti-inflammatory, antiviral, metabolic and anticancer\nactivity, targeting multiple indications with U.S. government and academic\ncollaborations intended for medical countermeasure development including for\nEbola virus disease, radiation exposure indications such as GI-Acute Radiation\nSyndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an\nongoing Phase 2 study in prostate cancer in combination with Bayer's\ndarolutamide; (ii) RHB-102 (Bekinda®), with a planned Phase 2\nproof-of-concept study for GLP-1/GIP receptor agonist-associated GI\nintolerance, positive results from a U.S. Phase 3 study for acute\ngastroenteritis and gastritis, positive results from a U.S. Phase 2 study\nfor IBS-D and potential UK submission for chemotherapy and radiotherapy\ninduced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals\n(EBR: HYL) for worldwide development and commercialization outside North\nAmerica; (iii) RHB-204, a next-generation optimized formulation of RHB-104,\nwith a planned Phase 2 study for Crohn's disease (based on RHB-104's positive\nPhase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an\noral broad-acting, host-directed, serine protease inhibitor with potential\nfor pandemic preparedness, including COVID-19 and also targeting multiple\ncancer and inflammatory gastrointestinal diseases.\n\nMore information about the Company is available at www.redhillbio.com\n(https://www.redhillbio.com/home/default.aspx)  / X.com/RedHillBio\n(https://x.com/RedHillBio) .\n\nForward Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of\nthe Private Securities Litigation Reform Act of 1995 and may discuss\ninvestment opportunities, stock analysis, financial performance, investor\nrelations, and market trends. Such statements may be preceded by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords and include, among others, the consummation of the offering and the\nsatisfaction of customary closing conditions related to the offering, the use\nof proceeds therefrom, the potential exercise of the series warrants and\npotential proceeds therefrom, potential acquisition of strategic products,\nstatements regarding the potential submission of Talicia® for UK Marketing\nAuthorisation and any approval thereof and statements regarding the potential\neffects of Talicia® in the treatment of Helicobacter pylori infection.\nForward-looking statements are based on certain assumptions and are subject to\nvarious known and unknown risks and uncertainties, many of which are beyond\nthe Company's control and cannot be predicted or quantified, and consequently,\nactual results may differ materially from those expressed or implied by such\nforward-looking statements. Such risks and uncertainties include, without\nlimitation: market and other conditions, the risk that the MAA submission for\nTalicia may not be approved; the risk that the Company will not succeed in its\nenforcement action against Kukbo, and if successful may not recover all or any\nof awards granted by the New York Supreme Court; the risk that opaganib does\nnot receive a priority review voucher, marketing exclusivity or accelerated\ndevelopment and review times; the risk that opaganib is not accepted into\nEbola virus disease control programs, or if accepted, that it does not\ndemonstrate efficacy; the risk that development of RHB-204 for Crohn's disease\nmay not be completed, or if completed may not be approved or may not achieve\ncommercial success; the risk that opaganib is not effective against the\nindications for which we develop our products; the risk that RHB-102 (Bekinda)\ndoes not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea;\nthe risk regarding the Company's ability to regain and maintain compliance\nwith Nasdaq's listing requirements, including the minimum bid price\nrequirement; the risk that the addition of new revenue generating products or\nout-licensing transactions will not occur; the risk that the Company will not\nreceive future milestone payments under its existing agreements or that they\nwill be less than anticipated; the risk of current uncertainty regarding U.S.\ngovernment research and development funding and that the U.S. government is\nunder no obligation to continue to support development of our products and can\ncease such support at any time; the risk that acceptance onto the RNCP Product\nDevelopment Pipeline or other governmental and non-governmental development\nprograms will not guarantee ongoing development or that any such development\nwill not be completed or successful; the risk that the FDA does not agree with\nthe Company's proposed development plans for its programs; the risk that the\nCompany's development programs and studies may not be successful and, even if\nsuccessful, such studies and results may not be sufficient for regulatory\napplications, including emergency use or marketing applications, and that\nadditional studies may be required; the risk that the Company will not\nsuccessfully commercialize its products; as well as risks and uncertainties\nassociated with (i) the initiation, timing, progress and results of the\nCompany's research, manufacturing, pre-clinical studies, clinical trials, and\nother therapeutic candidate development efforts, and the timing of the\ncommercial launch of its commercial products and ones it may acquire or\ndevelop in the future; (ii) the Company's ability to advance its therapeutic\ncandidates into clinical trials or to successfully complete its pre-clinical\nstudies or clinical trials or the development of any necessary commercial\ncompanion diagnostics; (iii) the extent and number and type of additional\nstudies that the Company may be required to conduct and the Company's receipt\nof regulatory approvals for its therapeutic candidates, and the timing of\nother regulatory filings, approvals and feedback; (iv) the manufacturing,\nclinical development, commercialization, and market acceptance of the\nCompany's therapeutic candidates and Talicia; (v) the Company's ability to\nsuccessfully commercialize and promote Talicia; (vi) the Company's ability to\nestablish and maintain corporate collaborations; (vii) the Company's ability\nto acquire products approved for marketing in the U.S. that achieve commercial\nsuccess and build its own marketing and commercialization capabilities; (viii)\nthe interpretation of the properties and characteristics of the Company's\ntherapeutic candidates and the results obtained with its therapeutic\ncandidates in research, pre-clinical studies or clinical trials; (ix) the\nimplementation of the Company's business model, strategic plans for its\nbusiness and therapeutic candidates; (x) the scope of protection the Company\nis able to establish and maintain for intellectual property rights covering\nits therapeutic candidates and its ability to operate its business without\ninfringing the intellectual property rights of others; (xi) parties from whom\nthe Company licenses its intellectual property defaulting in their obligations\nto the Company; (xii) the Company's ability to collect on its judgment against\nKukbo; (xiii) estimates of the Company's expenses, future revenues, capital\nrequirements and needs for additional financing; (xiv) the effect of patients\nsuffering adverse experiences using investigative drugs under the Company's\nExpanded Access Program; (xv) competition from other companies and\ntechnologies within the Company's industry; and (xvi) the hiring and\nemployment commencement date of executive managers. More detailed information\nabout the Company and the risk factors that may affect the realization of\nforward-looking statements is set forth in the Company's filings with the\nSecurities and Exchange Commission (SEC), including the Company's Annual\nReport on Form 20-F filed with the SEC on April 27, 2026. All forward-looking\nstatements included in this press release are made only as of the date of this\npress release. The Company assumes no obligation to update any written or oral\nforward-looking statement, whether as a result of new information, future\nevents or otherwise unless required by law.\n\nCategory: Financials\n\n([1])Talicia(®) (omeprazole magnesium, amoxicillin and rifabutin) is\nindicated for the treatment of H. pylori infection in adults. For full\nprescribing information see: www.Talicia.com (https://www.talicia.com/) .\n\nLogo -\nhttps://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg\n(https://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg)\n\nCompany contact:\n\nAdi Frish\nChief Corporate & Business Development Officer\nRedHill Biopharma\nadi@redhillbio.com (mailto:adi@redhillbio.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html\n(https://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html)\n\nSOURCE RedHill Biopharma Ltd.\n\n\n\n+972-54-6543-112\n\nPhoto: \nhttp://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-18T12:00:06.698628753Z","server_sent_at_ms":1781784006698},"received_at":"2026-06-18T12:00:06.864Z","source_url":"https://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html"},"analysis":{"id":"56987","press_release_id":"67572","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"RedHill Biopharma, a partner of Cumberland Pharmaceuticals, announced a private placement to raise up to $19.4 million, consisting of $6 million in upfront gross proceeds and potential warrant proceeds.\n\nThe offering involves the sale of 8,571,429 ADSs at $0.70 per share, accompanied by Series A-1 and A-2 warrants exercisable immediately.\n\nRedHill plans to use the net proceeds for working capital, R&D, and potential strategic product acquisitions, though no definitive acquisition agreements have been signed.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Partner RedHill raises $6M in private placement to fund R&D and strategic acquisitions."},"keyFigures":{"dealValueUsd":6000000,"offeringPrice":0.7,"sharesOffered":8571429,"customDimensions":{"series_a1_warrant_term":"5 years","series_a2_warrant_term":"18 months","potential_warrant_proceeds":"$13.4 million","series_a1_warrant_exercise_price":0.86,"series_a2_warrant_exercise_price":0.7}},"quotedText":"","namedEntities":{"people":[],"products":["Talicia","opaganib","ABC294640","RHB-102","Bekinda","RHB-204","RHB-107","upamostat","darolutamide"],"companies":[{"name":"RedHill Biopharma Ltd.","ticker":"RDHL","relationship":"partner"},{"name":"H.C. Wainwright & Co.","relationship":"placement agent"},{"name":"Hyloris Pharmaceuticals","ticker":"HYL","relationship":"partner"},{"name":"Bayer","relationship":"partner"}],"dollarAmounts":[{"amount":"$6 million","context":"upfront gross proceeds"},{"amount":"$13.4 million","context":"potential warrant proceeds"},{"amount":"$0.70","context":"purchase price per ADS"},{"amount":"$0.86","context":"Series A-1 warrant exercise price"}]},"materialImpact":{"score":2,"reasoning":"The announcement describes a private placement by RedHill Biopharma (RDHL), a commercial partner of CPIX. While the capital raise supports RedHill's operations, it is a relatively small financing ($6M upfront) and does not constitute a direct material event for Cumberland Pharmaceuticals (CPIX)."},"tickerRelevance":{"others":[{"ticker":"RDHL","relevance":"partner"},{"ticker":"HYL","relevance":"partner"}],"primary":"CPIX"},"globalImportance":12,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"partner_financing","sectorWeight":"health_care"}},"event_type":"offering","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"RedHill Biopharma, a partner of Cumberland Pharmaceuticals, announced a private placement to raise up to $19.4 million, consisting of $6 million in upfront gross proceeds and potential warrant proceeds.\n\nThe offering involves the sale of 8,571,429 ADSs at $0.70 per share, accompanied by Series A-1 and A-2 warrants exercisable immediately.\n\nRedHill plans to use the net proceeds for working capital, R&D, and potential strategic product acquisitions, though no definitive acquisition agreements have been signed.","key_figures":{"dealValueUsd":6000000,"offeringPrice":0.7,"sharesOffered":8571429,"customDimensions":{"series_a1_warrant_term":"5 years","series_a2_warrant_term":"18 months","potential_warrant_proceeds":"$13.4 million","series_a1_warrant_exercise_price":0.86,"series_a2_warrant_exercise_price":0.7}},"named_entities":{"people":[],"products":["Talicia","opaganib","ABC294640","RHB-102","Bekinda","RHB-204","RHB-107","upamostat","darolutamide"],"companies":[{"name":"RedHill Biopharma Ltd.","ticker":"RDHL","relationship":"partner"},{"name":"H.C. Wainwright & Co.","relationship":"placement agent"},{"name":"Hyloris Pharmaceuticals","ticker":"HYL","relationship":"partner"},{"name":"Bayer","relationship":"partner"}],"dollarAmounts":[{"amount":"$6 million","context":"upfront gross proceeds"},{"amount":"$13.4 million","context":"potential warrant proceeds"},{"amount":"$0.70","context":"purchase price per ADS"},{"amount":"$0.86","context":"Series A-1 warrant exercise price"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-18T12:29:28.877Z","global_importance":12,"audience_relevance":18,"importance_components":{"tickerTier":"small-cap","eventGravity":"partner_financing","sectorWeight":"health_care"}},"durationMs":169580,"modelName":"george-droid-qwen-72b"}}